aGVHD

AcronymDefinition
aGVHDAcute Graft Versus Host Disease
References in periodicals archive ?
However, the influences of HLA haplotypes on aGVHD have been rarely studied.
Impact of Human Leukocyte Antigen Loci and Haplotypes on Intestinal Acute Graft-versus-host Disease after Human Leukocyte Antigen-matched Sibling Peripheral Blood Stem Cell Transplantation
The successful outcome of the DSMB interim analysis using the trial's primary endpoint of Day 28 overall response is consistent with previously reported results in a pediatric Expanded Access Program (EAP) in children with steroid-refractory aGVHD.
Positive interim analysis in phase 3 trial for acute GvHD: Mesoblast prepares for commercial launch
The company plans to expand its use in adult patients with high-risk steroid-refractory aGVHD.
Mesoblast's MSC-100-IV successful in pre-specified interim futility analysis in phase three aGVHD trial
It is thought that both donor-derived alloreactive T cells similar to AGVHD and autoreactive T cell clones which can not be deleted as a result of thymic damage are involved (66, 67).
Hematopoetic stem cell transplantation in children
performed yet another study which sought to evaluate the use of ECP as second line therapy in patients with steroid-refractory aGvHD (50).
Extracorporeal photopheresis: a review on the immunological aspects and clinical applications
cGVHD can occur anytime from months to years after AHSCT and may or may not be preceded by episodes of aGVHD.
Clinical aspects of sclerodermatous type graft-versus-host disease after allogeneic hematopoietic cell transplantation / Allogeneik hematopoietik hucre nakli sonrasi sklerodermatoz tip graft-versus-host hastaliginin klinik yonleri
To support filing of a biologic license application to the FDA for regulatory approval, Mesoblast is conducting a 60-patient, open label Phase 3 trial using MSC-100-IV as front-line therapy in children with steroidrefractory aGvHD.
Stem cells increase survival of children with acute GvHD
As to TRM and III-IV grade aGVHD, the incidences of patients treated with G-BM were significantly lower chance to develop aGVHD and greater chance of survival than those treated with SS-BM [Figure 2]a and b.
Granulocyte Colony-stimulating Factor-primed Bone Marrow: An Excellent Stem-cell Source for Transplantation in Acute Myelocytic Leukemia and Chronic Myelocytic Leukemia
aGVHD of the liver develops within 2 to 10 weeks of alloHCT and occurs in approximately 40-60% of HLA-identical transplants [2,3,6,50,51].
Hepatic complications of allogeneic hematopoietic cell transplantation/Allojeneik hematopoetik hucre naklinin hepatik komplikasyonlari
ONTAK was well tolerated and demonstrated activity in treating steroid resistant aGVHD without an increase in relapse risk or unexpected infections.
Ligand's ONTAK Shows Potential to Treat Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma, and Graft-Versus-Host Disease, Four Abstracts from ASH Meeting Demonstrate
To support filing of a biologic license application (BLA) to the FDA for regulatory approval, Mesoblast is conducting a 60-patient, open label Phase 3 trial using MSC -100-IVas front-line therapy in children with steroidrefractory aGvHD.
Mesoblast licensee launches allogeneic cell therapy product in Japan
This large EAP data set continues to provide support for the benefit of MSC 100-IV for the treatment of aGVHD in children.
ISCO completes cell bank for parkinson's clinical trial
Acronyms browser ?
Full browser ?